Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company ...

Recursion has hit 4 milestones in its Sanofi partnership over the last 18 months, as well as 1 with Roche. Recursion's ATM facility is also likely to be used opportunistically to raise cash.

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday June 10, 2025 — 04:35 pm EDT Written by Eric Volkman for The Motley Fool -> ...

Summary I now rate Recursion Pharma a sell due to disappointing recent trial updates and uncertain future prospects. REC-4881's phase 2 TUPELO trial showed mixed results, with one patient ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a ...

Recently, two leading and long-established firms in the expanding AI drug discovery sector revealed an unexpected merger. In an approximate 75-25 agreement, Recursion Bio and Exscientia are set to ...

If you think you know everything about technology, think again! DigitalHub4Geeks.com unveiled is here to blow your mind with hidden tech secrets that most ...

Due to dynamic characteristic of demand response and stochastic nature of power generation, it brings great challenge to smart energy management. In this paper, a demand response model is created with ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted ...